Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation is offering multiple euro-denominated senior note series, including a floating-rate tranche and several fixed-rate tranches, to fund a portion of the proposed acquisition of Masimo Corporation. The prospectus supplement ties the fixed-rate notes to a special mandatory redemption if the Masimo merger is not consummated by the specified Outside Date.
The offering proceeds are intended to pay part of the cash consideration and costs for the Masimo Acquisition, which Danaher announced at $180 per share representing approximately $9.9 billion enterprise value. The fixed rate notes are subject to optional redemption provisions, change-of-control repurchase rights and certain structural and currency risks described herein.
Danaher Corporation reported solid first quarter 2026 results driven by earnings growth and strong cash generation. Revenue from continuing operations rose 3.5% year-over-year to $6.0 billion, while non-GAAP core revenue increased 0.5%.
Net earnings were $1.0 billion, or $1.45 per diluted share, and non-GAAP adjusted diluted net earnings per share grew 9.5% to $2.06. Operating cash flow reached $1.3 billion and non-GAAP free cash flow was $1.1 billion, underscoring strong cash conversion.
Management highlighted a steady recovery with strength in Bioprocessing and Life Sciences, partially offset by a lighter-than-typical respiratory season at Cepheid. Danaher also announced its intention to acquire Masimo Corporation and raised full-year 2026 adjusted diluted EPS guidance to a range of $8.35 to $8.55.
Danaher Corporation reported modest growth in early 2026 while preparing a major acquisition. For the quarter ended March 27, 2026, sales rose to $5.95 billion from $5.74 billion, with core sales up 0.5% and currency adding about 3%. Net earnings increased to $1.03 billion, and diluted EPS improved to $1.45 from $1.32, helped by higher sales and lower net interest expense.
The Biotechnology segment led performance with 7% core sales growth and a margin expansion to 29.7%, driven by stronger bioprocessing consumables demand. Life Sciences posted slight core growth and margin improvement, while Diagnostics core sales fell 4% as respiratory testing softened and China pricing pressure weighed, reducing its margin to 27.9%.
Danaher agreed to acquire Masimo Corporation, a patient monitoring and pulse oximetry specialist with 2025 revenue of about $1.5 billion, for roughly $9.9 billion in cash, to be included in Diagnostics. To support funding and liquidity, the company added a $5.0 billion 364‑day revolving credit facility and increased euro commercial paper, while also repaying €1.3 billion of 2026 Biopharma Euronotes. Operating cash flow was strong at $1.32 billion, lifting cash and equivalents to $5.70 billion.
Danaher Corporation entered into a new $5.0 billion 364-day revolving credit facility with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility expires on April 15, 2027 and can be converted at that date into term loans maturing one year later upon payment of a 0.50% fee on outstanding loans and satisfaction of conditions.
Borrowings bear variable interest, with Term SOFR loans priced at Term SOFR plus 58.5–108.5 basis points and Base Rate loans priced using a base formula plus a margin of 0–8.5 basis points, in each case depending on Danaher’s long‑term debt credit rating. Danaher also pays a 4.0 basis point annual facility fee on total commitments. The unsecured facility includes a covenant requiring a Consolidated Leverage Ratio of 0.65 to 1.00 or less and customary restrictions and events of default.
Danaher intends to use the facility to provide liquidity support for its U.S. dollar‑denominated commercial paper program and for general corporate purposes.
Danaher Corp: The Vanguard Group amends Schedule 13G to report no beneficial ownership. The filing states that after an internal realignment on January 12, 2026, certain Vanguard subsidiaries now report holdings separately and The Vanguard Group reports 0 shares and 0% beneficial ownership of Danaher common stock.
The filing explains the change is in accordance with SEC Release No. 34-39538 and is an administrative reallocation of reporting responsibilities within Vanguard; it does not describe purchases, sales, or cash flows in this excerpt.
Danaher Corporation reported 2025 continuing-operations results and presented its 2026 strategic priorities. Revenue was $24.6 billion, with $5.3 billion of free cash flow and adjusted diluted EPS of $7.80 (non-GAAP). The company generated 2% core revenue growth and 4.5% adjusted EPS growth year over year.
Management highlighted portfolio innovation across Biotechnology, Life Sciences and Diagnostics, continued deployment of the Danaher Business System and a bias to disciplined M&A, while noting risks including regulatory, geopolitical, competitive and reimbursement pressures.
Danaher Corporation is asking shareholders to elect eleven directors, ratify Ernst & Young LLP, approve an advisory vote on executive pay and approve an amended Omnibus Incentive Plan at its virtual 2026 annual meeting. The company highlights 2025 sales of $24.6 billion, operating profit of $4.7 billion and operating cash flow of $6.4 billion, supported by about $1.6 billion in research and development and $1.2 billion in capital expenditures.
Danaher also returned approximately $4.0 billion to shareholders through buybacks and dividends and agreed in February 2026 to acquire Masimo Corporation for about $9.9 billion in cash, including assumed debt and net of acquired cash, subject to regulatory and Masimo shareholder approvals. The proxy emphasizes a majority‑independent board with separate Chairman and CEO roles, majority voting for directors, proxy access, a 25% special meeting right and extensive compensation governance features such as clawbacks, robust stock ownership requirements and long-term, performance-based equity incentives.
Danaher Corp. notified the NYSE to remove a class of securities from listing. The Form 25 identifies the class as the guarantor of the 0.200% Senior Notes due 2026. The Exchange and the issuer state they complied with the procedures in 17 CFR 240.12d2-2 for voluntary withdrawal.
Leiken Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Danaher Corporation reported that SVP and Chief Legal Officer Jonathan Leiken received new equity awards. On March 1, 2026 he was granted 6,416 employee stock options at a price of $0.00 per share and 2,374 shares of common stock via restricted stock units. The RSUs vest 25% on each of the first four anniversaries of the March 1, 2026 grant date, while 50% of the options become exercisable on each of the third and fourth anniversaries of that grant date.
McGrew Matthew reported acquisition or exercise transactions in this Form 4 filing.
Danaher Corporation Executive Vice President Matthew McGrew received new equity awards on March 1, 2026. He was granted employee stock options for 16,039 shares at a grant price of $0.00 per share and a separate award of 5,935 shares of common stock, reported as restricted stock units (RSUs).
According to the disclosures, fifty percent of the options become exercisable on each of the third and fourth anniversaries of the March 1, 2026 grant date. For the RSUs, twenty-five percent vest on each of the first four anniversaries of the same grant date, creating a four-year vesting schedule tied to continued service.